Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.72 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.72 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.72 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12395821 | 0.88 | CYP2A6 (0.68) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL2121672 | 0.84 | CYP2A6 (1.00) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL2305968 | 0.84 | CYP2A6 (0.72) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL27163520 | 0.84 | CYP2A6 (0.72) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL19080614 | 0.83 | CYP2C9 (0.67) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL10130590 | 0.83 | CYP2C9 (0.67) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| Hydrochloric Acid SCHEMBL3606661 | 0.83 | CYP2A6 (0.97) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL11837821 | 0.81 | CYP2A6 (0.68) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL1233954 | 0.81 | CYP2A6 (0.68) | CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6 | |
| SCHEMBL805128 | 0.81 | NOTUM (0.68) | CYP2C9CYP2C19NOTUMCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110201649-A1 | AGRICULTURAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2009-12-31 | — | — | US | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7407942-B2 | 3,6-bridged 9,12-oxolides | EMATA PHARMACEUTICALS, INC (US) | 2008-08-05 | — | — | US | disclosed |
| WO-2008061189-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| US-7312201-B2 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7291602-B2 | 11,12-lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | AKR1C2, AKR1C3, AKR1C1 | CYP2A6 22/4885CYP2C9 11/4885CYP2C19 21/4885 |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | CYP2A6 22/4885CYP2C9 11/4885CYP2C19 21/4885 |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | CYP2A6 22/4885CYP2C9 11/4885CYP2C19 21/4885 |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | CYP2A6 150/4885CYP2C9 1/4885CYP2C19 4/4885 |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | CYP2C9, CYP2C19, CYP2D6 | CYP2A6 11/4885CYP2C9 1/4885CYP2C19 2/4885 |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | HDAC6, SI, HDAC3 | CYP2A6 130/4885CYP2C9 9/4885CYP2C19 11/4885 |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | CYP2A6 22/4885CYP2C9 11/4885CYP2C19 21/4885 |
| US-20110201649-A1 | AGRICULTURAL COMPOSITION | H1-0, H1-3, H1-2 | CYP2A6 4047/4885CYP2C9 2708/4885CYP2C19 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.